Interaction between hypnotic agents and the hypothalamic-pituitary-adrenocorticotropic axis during surgery;Modulation de l'axe hypothalamo-hypophyso-surrénalien par l'utilisation des agents hypnotiques dans le contexte chirurgical

Annales Francaises d'Anesthesie et de Reanimation

Volumn 33, Issue 4, 2014, Pages 256-265

  Besnier, E ^a,b   Clavier, T ^a,b   Castel, H ^b   Gandolfo, P ^b   Morin, F ^b   Tonon, M C ^b   Marguerite, C ^a   Veber, B ^a   Dureuil, B ^a   Compere V ^a,b  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b Université de Rouen   (France)

Author keywords

Anaesthetic agent; Hypothalamic pituitary adrenal axis; Steroids

Indexed keywords

ETOMIDATE; HYPNOTIC AGENT; CORTICOSTEROID; HYPNOTIC SEDATIVE AGENT;

ENDOCRINE SURGERY; HYPOTHALAMIC PITUITARY ADRENOCORTICOTROPIC AXIS; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MOLECULAR INTERACTION; SHORT SURVEY; BIOSYNTHESIS; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG INTERACTION; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; PEROPERATIVE COMPLICATION; SURGERY;

ADRENAL CORTEX HORMONES; DRUG INTERACTIONS; HUMANS; HYPNOTICS AND SEDATIVES; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INTRAOPERATIVE COMPLICATIONS; PITUITARY-ADRENAL SYSTEM; SURGICAL PROCEDURES, OPERATIVE;

EID: 84899953106     PISSN: 07507658     EISSN: 17696623     Source Type: Journal    
DOI: 10.1016/j.annfar.2014.01.022     Document Type: Short Survey

References (129)

1. Chrousos G.P. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995, 332:1351-1362.
2. Rhen T., Cidlowski J.A. Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. N Engl J Med 2005, 353:1711-1723.
3. Spiess J., Rivier J., Rivier C., Vale W. Primary structure of corticotropin-releasing factor from ovine hypothalamus. Proc Natl Acad Sci U S A 1981, 78:6517-6521.
4. Bonfiglio J.J., Inda C., Refojo D., Holsboer F., Arzt E., Silberstein S. The corticotropin-releasing hormone network and the hypothalamic-pituitary-adrenal axis: molecular and cellular mechanisms involved. Neuroendocrinology 2011, 94:12-20.
5. Miller W.L. Steroidogenic enzymes. Endocr Dev 2008, 13:1-18.
6. Breuner C.W., Orchinik M. Plasma binding proteins as mediators of corticosteroid action in vertebrates. J Endocrinol 2002, 175:99-112.
7. De Bosscher K., Vanden Berghe W., Vermeulen L., Plaisance S., Boone E., Haegeman G. Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc Natl Acad Sci U S A 2000, 97:3919-3924.
8. Keh D., Boehnke T., Weber-Cartens S., Schulz C., Ahlers O., Bercker S., et al. Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 2003, 167:512-520.
9. Chernow B., Alexander H.R., Smallridge R.C., Thompson W.R., Cook D., Beardsley D., et al. Hormonal responses to graded surgical stress. Arch Intern Med 1987, 147:1273-1278.
10. Taylor L.K., Auchus R.J., Baskin L.S., Miller W.L. Cortisol response to operative stress with anesthesia in healthy children. J Clin Endocrinol Metab 2013, 98:3687-3693.
11. Leopold S.S., Casnellie M.T., Warme W.J., Dougherty P.J., Wingo S.T., Shott S. Endogenous cortisol production in response to knee arthroscopy and total knee arthroplasty. J Bone Joint Surg Am 2003, 85-A(11):2163-2167.
12. Krupin T., Johnson M.F., Haimann M.H., Becker B. Plasma cortisol and elective cataract surgery. Am J Ophthalmol 1978, 85:475-477.
13. Naito Y., Fukata J., Tamai S., Seo N., Nakai Y., Mori K., et al. Biphasic changes in hypothalamo-pituitary-adrenal function during the early recovery period after major abdominal surgery. J Clin Endocrinol Metab 1991, 73:111-117.
14. Dimopoulou I., Tzanela M., Vassiliadi D., Mavrou I., Kopterides P., Orfanos S., et al. Pituitary-adrenal responses following major abdominal surgery. Hormones (Athens) 2008, 7:237-242.
15. Lin E., Calvano S.E., Lowry S.F. Inflammatory cytokines and cell response in surgery. Surgery 2000, 127:117-126.
16. Lindholm E., Seljeflot I., Aune E., Kirkebøen K.A. Proinflammatory cytokines and complement activation in salvaged blood from abdominal aortic aneurism surgery and total hip replacement surgery. Transfusion (Paris) 2012, 52:1761-1769.
17. Berkenbosch F., van Oers J., del Rey A., Tilders F., Besedovsky H. Corticotropin-releasing factor-producing neurons in the rat activated by interleukin-1. Science 1987, 238:524-526.
18. Uehara A., Gottschall P.E., Dahl R.R., Arimura A. Interleukin-1 stimulates ACTH release by an indirect action which requires endogenous corticotropin releasing factor. Endocrinology 1987, 121:1580-1582.
19. Matta S.G., Weatherbee J., Sharp B.M. A central mechanism is involved in the secretion of ACTH in response to IL-6 in rats: comparison to and interaction with IL-1 beta. Neuroendocrinology 1992, 56:516-525.
20. Yabuuchi K., Minami M., Katsumata S., Satoh M. Localization of type I interleukin-1 receptor mRNA in the rat brain. Brain Res Mol Brain Res 1994, 27:27-36.
21. Nadeau S., Rivest S. Effects of circulating tumor necrosis factor on the neuronal activity and expression of the genes encoding the tumor necrosis factor receptors (p55 and p75) in the rat brain: a view from the blood-brain barrier. Neuroscience 1999, 93:1449-1464.
22. O'Connell N.A., Kumar A., Chatzipanteli K., Mohan A., Agarwal R.K., Head C., et al. Interleukin-1 regulates corticosterone secretion from the rat adrenal gland through a catecholamine-dependent and prostaglandin E2-independent mechanism. Endocrinology 1994, 135:460-467.
23. Tominaga T., Fukata J., Naito Y., Usui T., Murakami N., Fukushima M., et al. Prostaglandin-dependent in vitro stimulation of adrenocortical steroidogenesis by interleukins. Endocrinology 1991, 128:526-531.
24. Barney M., Call G.B., McIlmoil C.J., Husein O.F., Adams A., Balls A.G., et al. Stimulation by interleukin-6 and inhibition by tumor necrosis factor of cortisol release from bovine adrenal zona fasciculata cells through their receptors. Endocrine 2000, 13:369-377.
25. Beishuizen A., Thijs L.G., Vermes I. Patterns of corticosteroid-binding globulin and the free cortisol index during septic shock and multitrauma. Intensive Care Med 2001, 27:1584-1591.
26. Lesur O., Roussy J.F., Chagnon F., Gallo-Payet N., Dumaine R., Sarret P., et al. Proven infection-related sepsis induces a differential stress response early after ICU admission. Crit Care 2010, 14:R131.
27. Annane D., Sébille V., Troché G., Raphaël J.C., Gajdos P., Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000, 283:1038-1045.
28. Salgado D.R., Rocco J.R., Rosso Verdeal J.C. Adrenal function in different subgroups of septic shock patients. Acta Anaesthesiol Scand 2008, 52:36-44.
29. Manglik S., Flores E., Lubarsky L., Fernandez F., Chhibber V.L., Tayek J.A. Glucocorticoid insufficiency in patients who present to the hospital with severe sepsis: a prospective clinical trial. Crit Care Med 2003, 31:1668-1675.
30. Marik P.E., Zaloga G.P. Adrenal insufficiency during septic shock. Crit Care Med 2003, 31:141-145.
31. Sarthi M., Lodha R., Vivekanandhan S., Arora N.K. Adrenal status in children with septic shock using low-dose stimulation test. Pediatr Crit Care Med 2007, 8:23-28.
32. Boonen E., Vervenne H., Meersseman P., Andrew R., Mortier L., Declercq P.E., et al. Reduced cortisol metabolism during critical illness. N Engl J Med 2013, 368:1477-1488.
33. Wang P., Ba Z.F., Jarrar D., Cioffi W.G., Bland K.I., Chaudry I.H. Mechanism of adrenal insufficiency following trauma and severe hemorrhage: role of hepatic 11beta-hydroxysteroid dehydrogenase. Arch Surg 1999, 134:394-401.
34. Annane D., Sébille V., Charpentier C., Bollaert P.E., François B., Korach J.M., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002, 288:862-871.
35. Moraes R.B., Friedman G., Tonietto T., Saltz H., Czepielewski M. Comparison of low and high dose cosyntropin stimulation tests in the diagnosis of adrenal insufficiency in septic shock patients. Horm Metab Res 2012, 44:296-301.
36. Magnotti M., Shimshi M. Diagnosing adrenal insufficiency: which test is best - the 1-microg or the 250-microg cosyntropin stimulation test?. Endocr Pract 2008, 14:233-238.
37. Cooper M.S., Stewart P.M. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003, 348:727-734.
38. De Jong M.F.C., Beishuizen A., Spijkstra J.J., Groeneveld A.B.J. Relative adrenal insufficiency as a predictor of disease severity, mortality, and beneficial effects of corticosteroid treatment in septic shock. Crit Care Med 2007, 35:1896-1903.
39. Cohan P., Wang C., McArthur D.L., Cook S.W., Dusick J.R., Armin B., et al. Acute secondary adrenal insufficiency after traumatic brain injury: a prospective study. Crit Care Med 2005, 33:2358-2366.
40. Stein D.M., Jessie E.M., Crane S., Kufera J.A., Timmons T., Rodriguez C.J., et al. Hyperacute adrenal insufficiency after hemorrhagic shock exists and is associated with poor outcomes. J Trauma Acute Care Surg 2013, 74:363-370. [discussion 370].
41. Lim S.Y., Kwon Y.S., Park M.R., Han S.G., Jeon K., Um S.W., et al. Prognostic significance of different subgroup classifications of critical illness-related corticosteroid insufficiency in patients with septic shock. Shock 2011, 36:345-349.
42. Saito T., Takanashi M., Gallagher E., Fuse A., Suzaki S., Inagaki O., et al. Corticosteroid effect on early beta-adrenergic down-regulation during circulatory shock: hemodynamic study and beta-adrenergic receptor assay. Intensive Care Med 1995, 21:204-210.
43. Bhagat K., Collier J., Vallance P. Local venous responses to endotoxin in humans. Circulation 1996, 94:490-497.
44. Oppert M., Schindler R., Husung C., Offermann K., Gräf K.J., Boenisch O., et al. Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med 2005, 33:2457-2464.
45. Laviolle B., Annane D., Fougerou C., Bellissant E. Gluco- and mineralocorticoid biological effects of a 7-day treatment with low doses of hydrocortisone and fludrocortisone in septic shock. Intensive Care Med 2012, 38:1306-1314.
46. Hebbar K.B., Stockwell J.A., Leong T., Fortenberry J.D. Incidence of adrenal insufficiency and impact of corticosteroid supplementation in critically ill children with systemic inflammatory syndrome and vasopressor-dependent shock. Crit Care Med 2011, 39:1145-1150.
47. Briegel J., Forst H., Haller M., Schelling G., Kilger E., Kuprat G., et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999, 27:723-732.
48. Annane D., Bellissant E., Bollaert P.E., Briegel J., Confalonieri M., De Gaudio R., et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 2009, 301:2362-2375.
49. Sligl W.I., Milner D.A., Sundar S., Mphatswe W., Majumdar S.R. Safety and efficacy of corticosteroids for the treatment of septic shock: a systematic review and meta-analysis. Clin Infect Dis 2009 1, 49:93-101.
50. Sprung C.L., Annane D., Keh D., Moreno R., Singer M., Freivogel K., et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008, 358:111-124.
51. Marik P.E., Pastores S.M., Annane D., Meduri G.U., Sprung C.L., Arlt W., et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008, 36:1937-1949.
52. Dellinger R.P., Levy M.M., Rhodes A., Annane D., Gerlach H., Opal S.M., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013, 39:165-228.
53. Hoen S., Mazoit J.X., Asehnoune K., Brailly-Tabard S., Benhamou D., Moine P., et al. Hydrocortisone increases the sensitivity to alpha1-adrenoceptor stimulation in humans following hemorrhagic shock. Crit Care Med 2005, 33:2737-2743.
54. Roquilly A., Mahe P.J., Seguin P., Guitton C., Floch H., Tellier A.C., et al. Hydrocortisone therapy for patients with multiple trauma: the randomized controlled HYPOLYTE study. JAMA 2011, 305:1201-1209.
55. Gelissen H.P., Epema A.H., Henning R.H., Krijnen H.J., Hennis P.J., den Hertog A. Inotropic effects of propofol, thiopental, midazolam, etomidate, and ketamine on isolated human atrial muscle. Anesthesiology 1996, 84:397-403.
56. Latson T.W., McCarroll S.M., Mirhej M.A., Hyndman V.A., Whitten C.W., Lipton J.M. Effects of three anesthetic induction techniques on heart rate variability. J Clin Anesth 1992, 4:265-276.
57. Ledingham I.M., Watt I. Influence of sedation on mortality in critically ill multiple trauma patients. Lancet 1983, 1:1270.
58. Wagner R.L., White P.F., Kan P.B., Rosenthal M.H., Feldman D. Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med 1984, 310:1415-1421.
59. Weber M.M., Lang J., Abedinpour F., Zeilberger K., Adelmann B., Engelhardt D. Different inhibitory effect of etomidate and ketoconazole on the human adrenal steroid biosynthesis. J Mol Med 1993, 71:933-938.
60. Allolio B., Dörr H., Stuttmann R., Knorr D., Engelhardt D., Winkelmann W. Effect of a single bolus of etomidate upon eight major corticosteroid hormones and plasma ACTH. Clin Endocrinol (Oxf) 1985, 22:281-286.
61. De Coster R., Helmers J.H., Noorduin H. Effect of etomidate on cortisol biosynthesis: site of action after induction of anaesthesia. Acta Endocrinol (Copenh) 1985, 110:526-531.
62. Hohl C.M., Kelly-Smith C.H., Yeung T.C., Sweet D.D., Doyle-Waters M.M., Schulzer M. The effect of a bolus dose of etomidate on cortisol levels, mortality, and health services utilization: a systematic review. Ann Emerg Med 2010, 56. 105-113.e5.
63. Komatsu R., You J., Mascha E.J., Sessler D.I., Kasuya Y., Turan A. Anesthetic induction with etomidate, rather than propofol, is associated with increased 30-day mortality and cardiovascular morbidity after noncardiac surgery. Anesth Analg 2013, 117:1329-1337.
64. Wagner C.E., Bick J.S., Johnson D., Ahmad R., Han X., Ehrenfeld J.M., et al. Etomidate use and postoperative outcomes among cardiac surgery patients. Anesthesiology 2014, 120:579-589.
65. Schenarts C.L., Burton J.H., Riker R.R. Adrenocortical dysfunction following etomidate induction in emergency department patients. Acad Emerg Med 2001, 8:1-7.
66. Absalom A., Pledger D., Kong A. Adrenocortical function in critically ill patients 24h after a single dose of etomidate. Anaesth (Lond) 1999, 54:861-867.
67. Vinclair M., Broux C., Faure P., Brun J., Genty C., Jacquot C., et al. Duration of adrenal inhibition following a single dose of etomidate in critically ill patients. Intensive Care Med 2007, 34:714-719.
68. Payen J.F., Dupuis C., Trouve-Buisson T., Vinclair M., Broux C., Bouzat P., et al. Corticosteroid after etomidate in critically ill patients: a randomized controlled trial. Crit Care Med 2012, 40:29-35.
69. Asehnoune K., Mahe P.J., Seguin P., Jaber S., Jung B., Guitton C., et al. Etomidate increases susceptibility to pneumonia in trauma patients. Intensive Care Med 2012, 38:1673-1682.
70. Cuthbertson B.H., Sprung C.L., Annane D., Chevret S., Garfield M., Goodman S., et al. The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock. Intensive Care Med 2009, 35:1868-1876.
71. Tekwani K.L., Watts H.F., Rzechula K.H., Sweis R.T., Kulstad E.B. A prospective observational study of the effect of etomidate on septic patient mortality and length of stay. Acad Emerg Med 2009, 16:11-14.
72. Jung B., Clavieras N., Nougaret S., Molinari N., Roquilly A., Cisse M., et al. Effects of etomidate on complications related to intubation and on mortality in septic shock patients treated with hydrocortisone: a propensity score analysis. Crit Care 2012, 16:R224.
73. Albert S.G., Ariyan S., Rather A. The effect of etomidate on adrenal function in critical illness: a systematic review. Intensive Care Med 2011, 37:901-910.
74. Chan C.M., Mitchell A.L., Shorr A.F. Etomidate is associated with mortality and adrenal insufficiency in sepsis: a meta-analysis. Crit Care Med 2012, 40:2945-2953.
75. Poulos T.L., Howard A.J. Crystal structures of metyrapone- and phenylimidazole-inhibited complexes of cytochrome P-450cam. Biochemistry (Mosc) 1987, 26:8165-8174.
76. Ullerås E., Ohlsson A., Oskarsson A. Secretion of cortisol and aldosterone as a vulnerable target for adrenal endocrine disruption - screening of 30 selected chemicals in the human H295R cell model. J Appl Toxicol 2008, 28:1045-1053.
77. Shanmugasundararaj S., Zhou X., Neunzig J., Bernhardt R., Cotten J.F., Ge R., et al. Carboetomidate: an analog of etomidate that interacts weakly with 11β-hydroxylase. Anesth Analg 2013, 116:1249-1256.
78. Cotten J.F., Forman S.A., Laha J.K., Cuny G.D., Husain S.S., Miller K.W., et al. Carboetomidate: a pyrrole analogue of etomidate designed not to suppress adrenocortical function. Anesthesiology 2010, 112:637-644.
79. Ivankovich A.D., Miletich D.J., Reimann C., Albrecht R.F., Zahed B. Cardiovascular effects of centrally administered ketamine in goats. Anesth Analg 1974, 53:924-933.
80. Hergovich N., Singer E., Agneter E., Eichler H.G., Graselli U., Simhandl C., et al. Comparison of the effects of ketamine and memantine on prolactin and cortisol release in men. A randomized, double-blind, placebo-controlled trial. Neuropsychopharmacololgy 2001, 24:590-593.
81. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994, 51:199-214.
82. Du J., Huang Y.G., Yu X.R., Zhao N. Effects of preoperative ketamine on the endocrine-metabolic and inflammatory response to laparoscopic surgery. Chin Med J (Engl) 2011, 124:3721-3725.
83. Bhat G.K., Mahesh V.B., Chu Z.W., Chorich L.P., Zamorano P.L., Brann D.W. Localization of the N-methyl-D-aspartate R1 receptor subunit in specific anterior pituitary hormone cell types of the female rat. Neuroendocrinology 1995, 62:178-186.
84. Bhat G.K., Mahesh V.B., Lamar C.A., Ping L., Aguan K., Brann D.W. Histochemical localization of nitric oxide neurons in the hypothalamus: association with gonadotropin-releasing hormone neurons and co-localization with N-methyl-D-aspartate receptors. Neuroendocrinology 1995, 62:187-197.
85. Schwendt M., Jezová D. Gene expression of NMDA receptor subunits in rat adrenals under basal and stress conditions. J Physiol Pharmacol 2001, 52:719-727.
86. Shaked G., Czeiger D., Dukhno O., Levy I., Artru A.A., Shapira Y., et al. Ketamine improves survival and suppresses IL-6 and TNF alpha production in a model of Gram-negative bacterial sepsis in rats. Resuscitation 2004, 62:237-242.
87. Taniguchi T., Takemoto Y., Kanakura H., Kidani Y., Yamamoto K. The dose-related effects of ketamine on mortality and cytokine responses to endotoxin-induced shock in rats. Anesth Analg 2003, 97:1769-1772.
88. Welters I.D., Hafer G., Menzebach A., Mühling J., Neuhäuser C., Browning P., et al. Ketamine inhibits transcription factors activator protein 1 and nuclear factor-kappaB, interleukin-8 production, as well as CD11b and CD16 expression: studies in human leukocytes and leukocytic cell lines. Anesth Analg 2010, 110:934-941.
89. Wu G.J., Chen T.L., Ueng Y.F., Chen R.M. Ketamine inhibits tumor necrosis factor-alpha and interleukin-6 gene expressions in lipopolysaccharide-stimulated macrophages through suppression of toll-like receptor 4-mediated c-Jun N-terminal kinase phosphorylation and activator protein-1 activation. Toxicol Appl Pharmacol 2008, 228:105-113.
90. Jabre P., Combes X., Lapostolle F., Dhaouadi M., Ricard-Hibon A., Vivien B., et al. Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial. Lancet 2009, 374:293-300.
91. Dalens B. Traité d'anesthésie générale, chapitre 2 2002, Édition Arnette, Paris.
92. Ha H.R., Funk B., Maitre P.O., Zbinden A.M., Follath F., Thomson D.A. Midazolam in plasma from hospitalized patients as measured by gas-liquid chromatography with electron-capture detection. Clin Chem 1988, 34:676-679.
93. Holloway C.D., Kenyon C.J., Dowie L.J., Corrie J.E., Gray C.E., Fraser R. Effect of the benzodiazepines diazepam, des-N-methyldiazepam and midazolam on corticosteroid biosynthesis in bovine adrenocortical cells in vitro; location of site of action. J Steroid Biochem 1989, 33:219-225.
94. Arvat E., Maccagno B., Ramunni J., Di Vito L., Giordano R., Gianotti L., et al. The inhibitory effect of alprazolam, a benzodiazepine, overrides the stimulatory effect of metyrapone-induced lack of negative cortisol feedback on corticotroph secretion in humans. J Clin Endocrinol Metab 1999, 84:2611-2615.
95. Grottoli S., Maccagno B., Ramunni J., Di Vito L., Giordano R., Gianotti L., et al. Alprazolam, a benzodiazepine, does not modify the ACTH and cortisol response to hCRH and AVP, but blunts the cortisol response to ACTH in humans. J Endocrinol Invest 2002, 25:420-425.
96. Crozier T.A., Beck D., Schlaeger M., Wuttke W., Kettler D. Endocrinological changes following etomidate, midazolam, or methohexital for minor surgery. Anesthesiology 1987, 66:628-635.
97. Thomson I., Fraser R., Kenyon C.J. Regulation of adrenocortical steroidogenesis by benzodiazepines. J Steroid Biochem Mol Biol 1995, 53:75-79.
98. Kalogeras K.T., Calogero A.E., Kuribayiashi T., Khan I., Gallucci W.T., Kling M.A., et al. In vitro and in vivo effects of the triazolobenzodiazepine alprazolam on hypothalamic-pituitary-adrenal function: pharmacological and clinical implications. J Clin Endocrinol Metab 1990, 70:1462-1471.
99. Al-Damluji S., Rees L.H. Effects of catecholamines on secretion of adrenocorticotrophic hormone (ACTH) in man. J Clin Pathol 1987, 40:1098-1107.
100. Ekbom K., Kalman S., Jakobsson J., Marcus C. Effects of midazolam and nitrous oxide on endocrine and metabolic measurements in children. Horm Res Paediatr 2012, 77:309-319.
101. Mikkelsen J.D., Søderman A., Kiss A., Mirza N. Effects of benzodiazepines receptor agonists on the hypothalamic-pituitary-adrenocortical axis. Eur J Pharmacol 2005, 519:223-230.
102. Krueger K.E., Papadopoulos V. Peripheral-type benzodiazepine receptors mediate translocation of cholesterol from outer to inner mitochondrial membranes in adrenocortical cells. J Biol Chem 1990, 265:15015-15022.
103. Yanagibashi K., Ohno Y., Nakamichi N., Matsui T., Hayashida K., Takamura M., et al. Peripheral-type benzodiazepine receptors are involved in the regulation of cholesterol side chain cleavage in adrenocortical mitochondria. J Biochem (Tokyo) 1989, 106:1026-1029.
104. Mikkelsen J.D., Bundzikova J., Larsen M.H., Hansen H.H., Kiss A. GABA regulates the rat hypothalamic-pituitary-adrenocortical axis via different GABA-A receptor alpha-subtypes. Ann N Y Acad Sci 2008, 1148:384-392.
105. Fukuda K., Uetsuki N., Uga H., Hashiguchi M., Sato M., Hisano T., et al. Potentiation of proopiomelanocortin gene expression in cultured pituitary cells by benzodiazepines. Anesthesiology 2003, 98:1172-1177.
106. Vargas M.L., Abella C., Hernandez J. Diazepam increases the hypothalamic-pituitary-adrenocortical (HPA) axis activity by a cyclic AMP-dependent mechanism. Br J Pharmacol 2001, 133:1355-1361.
107. Kenyon C.J., McNeil L.M., Fraser R. Comparison of the effects of etomidate, thiopentone and propofol on cortisol synthesis. Br J Anaesth 1985, 57:509-511.
108. Lambert A., Mitchell R., Robertson W.R. Effect of propofol, thiopentone and etomidate on adrenal steroidogenesis in vitro. Br J Anaesth 1985, 57:505-508.
109. Van Hemelrijck J., Weekers F., Van Aken H., Bouillon R., Heyns W. Propofol anesthesia does not inhibit stimulation of cortisol synthesis. Anesth Analg 1995, 80:573-576.
110. Dispersyn G., Sage D., Challet E., Pain L., Touitou Y. Plasma corticosterone in rats is specifically increased at recovery from propofol anesthesia without concomitant rise of plasma ACTH. Chronobiol Int 2009, 26:697-708.
111. Duthie D.J., Fraser R., Nimmo W.S. Effect of induction of anaesthesia with etomidate on corticosteroid synthesis in man. Br J Anaesth 1985, 57:156-159.
112. Kostopanagiotou G., Kalimeris K., Christodoulaki K., Nastos C., Papoutsidakis N., Dima C., et al. The differential impact of volatile and intravenous anaesthetics on stress response in the swine. Hormones (Athens) 2010, 9:67-75.
113. Mizutani A., Hattori S., Yoshitake S., Kitano T., Noguchi T. Effect of additional general anesthesia with propofol, midazolam or sevoflurane on stress hormone levels in hysterectomy patients, receiving epidural anesthesia. Acta Anaesthesiol Belg 1998, 49:133-139.
114. Nishiyama T., Yamashita K., Yokoyama T. Stress hormone changes in general anesthesia of long duration: isoflurane-nitrous oxide vs sevoflurane-nitrous oxide anesthesia. J Clin Anesth 2005, 17:586-591.
115. Hoy S.M., Keating G.M. Dexmedetomidine: a review of its use for sedation in mechanically ventilated patients in an intensive care setting and for procedural sedation. Drugs 2011, 71:1481-1501.
116. Jakob S.M., Ruokonen E., Grounds R.M., Sarapohja T., Garratt C., Pocock S.J., et al. Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. JAMA 2012, 307:1151-1160.
117. Maze M., Virtanen R., Daunt D., Banks S.J.M., Stover E.P., Feldman D. Effects of dexmedetomidine, a novel imidazole sedative-anesthetic agent, on adrenal steroidogenesis. Anesth Analg 1991, 73:204-208.
118. Aho M., Scheinin M., Lehtinen A.M., Erkola O., Vuorinen J., Korttila K. Intramuscularly administered dexmedetomidine attenuates hemodynamic and stress hormone responses to gynecologic laparoscopy. Anesth Analg 1992, 75:932-939.
119. Venn R.M., Bryant A., Hall G.M., Grounds R.M. Effects of dexmedetomidine on adrenocortical function, and the cardiovascular, endocrine and inflammatory responses in post-operative patients needing sedation in the intensive care unit. Br J Anaesth 2001, 86:650-656.
120. Harlin C.A., Parker C.R. Investigation of the effect of interleukin-1 beta on steroidogenesis in the human fetal adrenal gland. Steroids 1991, 56:72-76.
121. Roh M.S., Drazenovich K.A., Barbose J.J., Dinarello C.A., Cobb C.F. Direct stimulation of the adrenal cortex by interleukin-1. Surgery 1987, 102:140-146.
122. Whitcomb R.W., Linehan W.M., Wahl L.M., Knazek R.A. Monocytes stimulate cortisol production by cultured human adrenocortical cells. J Clin Endocrinol Metab 1988, 66:33-38.
123. Winter J.S., Gow K.W., Perry Y.S., Greenberg A.H. A stimulatory effect of interleukin-1 on adrenocortical cortisol secretion mediated by prostaglandins. Endocrinology 1990, 127:1904-1909.
124. Andreis P.G., Neri G., Belloni A.S., Mazzocchi G., Kasprzak A., Nussdorfer G.G. Interleukin-1 beta enhances corticosterone secretion by acting directly on the rat adrenal gland. Endocrinology 1991, 129:53-57.
125. Andreis P.G., Neri G., Meneghelli V., Mazzocchi G., Nussdorfer G.G. Effects of interleukin-1 beta on the renin-angiotensin-aldosterone system in rats. Res Exp Med (Berl) 1992, 192:1-6.
126. Natarajan R., Ploszaj S., Horton R., Nadler J. Tumor necrosis factor and interleukin-1 are potent inhibitors of angiotensin-II-induced aldosterone synthesis. Endocrinology 1989, 125:3084-3089.
127. Salas M.A., Evans S.W., Levell M.J., Whicher J.T. Interleukin-6 and ACTH act synergistically to stimulate the release of corticosterone from adrenal gland cells. Clin Exp Immunol 1990, 79:470-473.
128. Jäättelä M., Carpén O., Stenman U.H., Saksela E. Regulation of ACTH-induced steroidogenesis in human fetal adrenals by rTNF-alpha. Mol Cell Endocrinol 1990, 68:R31-R36.
129. Gwosdow A.R., O'Connell N.A., Spencer J.A., Kumar M.S., Agarwal R.K., Bode H.H., et al. Interleukin-1-induced corticosterone release occurs by an adrenergic mechanism from rat adrenal gland. Am J Physiol 1992, 63:461-466.